Non-Hodgkin Lymphoma: Diagnosis and Treatment

Mayo Clinic Proceedings

Volumn 90, Issue 8, 2015, Pages 1152-1163

  Ansell, Stephen M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BELINOSTAT; BENDAMUSTINE; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; DOXYCYCLINE; ETOPOSIDE; FOLINIC ACID; FOSTAMATINIB; IBRUTINIB; IDELALISIB; IFOSFAMIDE; LENALIDOMIDE; METHOTREXATE; PRALATREXATE; PREDNISONE; RITUXIMAB; ROMIDEPSIN; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE;

ADVANCED CANCER; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL CLEARANCE; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DRUG MEGADOSE; DRUG RESPONSE; FOLLICULAR LYMPHOMA; HELICOBACTER PYLORI; HUMAN; LARGE CELL LYMPHOMA; LYMPH NODE METASTASIS; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; ORNITHOSIS; PERIPHERAL T CELL LYMPHOMA; PHASE 3 CLINICAL TRIAL (TOPIC); RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RISK ASSESSMENT; SPLENECTOMY; T CELL LYMPHOMA; LYMPHOMA, NON-HODGKIN; MORTALITY; PROGNOSIS;

HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; PROGNOSIS;

EID: 84938598515     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.04.025     Document Type: Conference Paper

References (100)

1. S.H. Swedlow, E. Campo, N.L. Harris, and et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008 International Agency for Research on Cancer Lyon, France
2. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 1 2015 5 29
3. R. Küppers Mechanisms of B-cell lymphoma pathogenesis Nat Rev Cancer 5 4 2005 251 262
4. M. Vockerodt, L.F. Yap, C. Shannon-Lowe, and et al. The Epstein-Barr virus and the pathogenesis of lymphoma J Pathol 235 2 2015 312 322
5. E.S. Jaffe Classification of natural killer (NK) cell and NK-like T-cell malignancies Blood 87 4 1996 1207 1210
6. M.R. Smith, and W.C. Greene Molecular biology of the type I human T-cell leukemia virus (HTLV-I) and adult T-cell leukemia J Clin Invest 87 3 1991 761 766
7. E. Cesarman, Y. Chang, P.S. Moore, J.W. Said, and D.M. Knowles Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas N Engl J Med 332 18 1995 1186 1191
8. M. Ulcickas Yood, C.P. Quesenberry Jr., D. Guo, and et al. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection Hepatology 46 1 2007 107 112
9. T. Hussell, P.G. Isaacson, J.E. Crabtree, and J. Spencer The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 342 8871 1993 571 574
10. D. Saadoun, F. Suarez, F. Lefrere, and et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 105 1 2005 74 76
11. A. Husain, D. Roberts, B. Pro, P. McLaughlin, and B. Esmaeli Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics Cancer 110 4 2007 809 815
12. J.R. Goodlad, M.M. Davidson, K. Hollowood, P. Batstone, and D.O. Ho-Yen Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin Histopathology 37 6 2000 501 508
13. A.F. List, J.P. Greer, J.B. Cousar, and et al. Non-Hodgkin's lymphoma after treatment of Hodgkin's disease: association with Epstein-Barr virus Ann Intern Med 105 5 1986 668 673
14. S.A. Rosenberg Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas Cancer Treat Rep 61 6 1977 1023 1027
15. B.D. Cheson, R.I. Fisher, S.F. Barrington, et al. Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification J Clin Oncol 32 27 2014 3059 3068
16. P. Solal-Céligny, P. Roy, P. Colombat, and et al. Follicular lymphoma international prognostic index Blood 104 5 2004 1258 1265
17. A predictive model for aggressive non-Hodgkin's lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project N Engl J Med 329 14 1993 987 994
18. A. Rosenwald, G. Wright, W.C. Chan, and et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 346 25 2002 1937 1947
19. C.P. Hans, D.D. Weisenburger, T.C. Greiner, and et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103 1 2004 275 282
20. X. Xing, and A.L. Feldman Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous Adv Anat Pathol 22 1 2015 29 49
21. M.E. Juweid, G.A. Wiseman, J.M. Vose, and et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography J Clin Oncol 23 21 2005 4652 4661
22. S.F. Barrington, N.G. Mikhaeel, L. Kostakoglu, and et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group J Clin Oncol 32 27 2014 3048 3058
23. J.S. Abramson T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management Oncologist 11 4 2006 384 392
24. S.M. Aukema, R. Siebert, E. Schuuring, and et al. Double-hit B-cell lymphomas Blood 117 8 2011 2319 2331
25. S. Barrans, S. Crouch, A. Smith, and et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab J Clin Oncol 28 20 2010 3360 3365
26. C.J. Stasik, H. Nitta, W. Zhang, and et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma Haematologica 95 4 2010 597 603
27. T.P. Miller, S. Dahlberg, J.R. Cassady, and et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma N Engl J Med 339 1 1998 21 26
28. M. Pfreundschuh, A.D. Ho, E. Cavallin-Stahl, et al. MabThera International Trial (MInT) Group Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study Lancet. Oncol 9 5 2008 435 444
29. Lamy T, Damaj G, Gyan E, et al. R-CHOP with or without radiotherapy in non-bulky limited-stage diffuse large B cell lymphoma (DLBCL): preliminary results of the prospective randomized phase III 02-03 trial from the Lysa/Goelams Group. Paper presented at: 56th American Society of Hematology Annual Meeting and Exposition; December 6-9, 2014; San Francisco, CA. Abstract 393.
30. B. Coiffier, E. Lepage, J. Briere, and et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 4 2002 235 242
31. P. Feugier, A. Van Hoof, C. Sebban, and et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 18 2005 4117 4126
32. T.M. Habermann, E.A. Weller, V.A. Morrison, and et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma J Clin Oncol 24 19 2006 3121 3127
33. M. Pfreundschuh, J. Schubert, M. Ziepert, et al. German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol 9 2 2008 105 116
34. D. Cunningham, E.A. Hawkes, A. Jack, and et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles Lancet 381 9880 2013 1817 1826
35. C. Récher, B. Coiffier, C. Haioun, and et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial Lancet 378 9806 2011 1858 1867
36. A. Greb, J. Bohlius, D. Schiefer, G. Schwarzer, H. Schulz, and A. Engert High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults Cochrane Database Syst Rev 1 2008 CD004024
37. N. Schmitz, M. Nickelsen, M. Ziepert, et al. German High-Grade Lymphoma Study Group (DSHNHL) Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1) Lancet Oncol 13 12 2012 1250 1259
38. P.J. Stiff, J.M. Unger, J.R. Cook, and et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma N Engl J Med 369 18 2013 1681 1690
39. G.S. Nowakowski, B. LaPlant, W.R. Macon, and et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study J Clin Oncol 33 3 2015 251 257
40. A. Younes, C. Thieblemont, F. Morschhauser, and et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study Lancet Oncol 15 9 2014 1019 1026
41. C. Gisselbrecht, B. Glass, N. Mounier, and et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study [abstract] J Clin Oncol 27 15, suppl 2009 8509
42. T. Philip, C. Guglielmi, A. Hagenbeek, and et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 333 23 1995 1540 1545
43. C. Gisselbrecht, N. Schmitz, N. Mounier, and et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma J Clin Oncol 30 36 2012 4462 4469
44. R.J. van Kampen, C. Canals, H.C. Schouten, and et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry J Clin Oncol 29 10 2011 1342 1348
45. G. Ott, T. Katzenberger, A. Lohr, and et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3 Blood 99 10 2002 3806 3812
46. B.K. Link, M.J. Maurer, G.S. Nowakowski, and et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource J Clin Oncol 31 26 2013 3272 3278
47. M. Federico, M. Bellei, L. Marcheselli, and et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project J Clin Oncol 27 27 2009 4555 4562
48. B.E. Wahlin, O.E. Yri, E. Kimby, and et al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times Br J Haematol 156 2 2012 225 233
49. B.A. Guadagnolo, S. Li, D. Neuberg, and et al. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy Int J Radiat Oncol Biol Phys 64 3 2006 928 934
50. P. Solal-Céligny, M. Bellei, L. Marcheselli, and et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database J Clin Oncol 30 31 2012 3848 3853
51. R.I. Fisher, M. LeBlanc, O.W. Press, D.G. Maloney, J.M. Unger, and T.P. Miller New treatment options have changed the survival of patients with follicular lymphoma J Clin Oncol 23 33 2005 8447 8452
52. K.M. Ardeshna, W. Qian, P. Smith, and et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial Lancet Oncol 15 4 2014 424 435
53. B.S. Kahl, F. Hong, M.E. Williams, and et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402 J Clin Oncol 32 28 2014 3096 3102
54. L.I. Wagner, F. Zhao, F. Hong, and et al. Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT) J Clin Oncol 33 7 2015 740 748
55. M.J. Rummel, N. Niederle, G. Maschmeyer, et al. Study group indolent Lymphomas (StiL) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial [published correction appears in Lancet. 2013;381(9873):1184] Lancet 381 9873 2013 1203 1210
56. I.W. Flinn, R. van der Jagt, B.S. Kahl, and et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Blood 123 19 2014 2944 2952
57. G. Salles, J.F. Seymour, F. Offner, and et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial [published correction appears in Lancet. 2011;377(9772):1154] Lancet 377 9759 2011 42 51
58. H. Hochster, E. Weller, R.D. Gascoyne, and et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study J Clin Oncol 27 10 2009 1607 1614
59. F. Morschhauser, J. Radford, A. Van Hoof, and et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma J Clin Oncol 26 32 2008 5156 5164
60. M. Al Khabori, J.R. de Almeida, G.H. Guyatt, J. Kuruvilla, and M. Crump Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis J Natl Cancer Inst 104 1 2012 18 28
61. N.H. Fowler, R.E. Davis, S. Rawal, and et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial Lancet Oncol 15 12 2014 1311 1318
62. A. Hagenbeek, O. Gadeberg, P. Johnson, and et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial Blood 111 12 2008 5486 5495
63. F. Morschhauser, J.P. Leonard, L. Fayad, and et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results J Clin Oncol 27 20 2009 3346 3353
64. F. Morschhauser, P. Marlton, U. Vitolo, and et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma Ann Oncol 21 9 2010 1870 1876
65. G.A. Salles, F. Morschhauser, P. Solal-Céligny, and et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study J Clin Oncol 31 23 2013 2920 2926
66. J. Radford, A. Davies, G. Cartron, and et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000) Blood 122 7 2013 1137 1143
67. A.K. Gopal, B.S. Kahl, S. de Vos, and et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma N Engl J Med 370 11 2014 1008 1018
68. R.H. Advani, J.J. Buggy, J.P. Sharman, and et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies J Clin Oncol 31 1 2013 88 94
69. J.W. Friedberg, J. Sharman, J. Sweetenham, and et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 115 13 2010 2578 2585
70. H.C. Schouten, W. Qian, S. Kvaloy, and et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial J Clin Oncol 21 21 2003 3918 3927
71. K. van Besien, F.R. Loberiza Jr., R. Bajorunaite, and et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma Blood 102 10 2003 3521 3529
72. A.M. Evens, A. Vanderplas, A.S. LaCasce, and et al. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project Cancer 119 20 2013 3662 3671
73. L. Nygren, S. Baumgartner Wennerholm, M. Klimkowska, B. Christensson, E. Kimby, and B. Sander Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma Blood 119 18 2012 4215 4223
74. J.E. Romaguera, L.J. Medeiros, F.B. Hagemeister, and et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma [published correction appears in Cancer. 2003;97(12):3131] Cancer 97 3 2003 586 591
75. P. Martin, A. Chadburn, P. Christos, and et al. Outcome of deferred initial therapy in mantle-cell lymphoma J Clin Oncol 27 8 2009 1209 1213
76. H.C. Kluin-Nelemans, E. Hoster, O. Hermine, and et al. Treatment of older patients with mantle-cell lymphoma N Engl J Med 367 6 2012 520 531
77. J.E. Romaguera, L.E. Fayad, L. Feng, and et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma [published correction appears in Br J Haematol. 2010;151(1):111] Br J Haematol 150 2 2010 200 208
78. M. Dreyling, G. Lenz, E. Hoster, and et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network Blood 105 7 2005 2677 2684
79. C.H. Geisler, A. Kolstad, A. Laurell, et al. Nordic Lymphoma Group Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur [published correction appears in Br J Haematol. 2012;158(6):815-816] Br J Haematol 158 3 2012 355 362
80. O.A. O'Connor, C. Moskowitz, C. Portlock, and et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial Br J Haematol 145 1 2009 34 39
81. H.E. Eve, S. Carey, S.J. Richardson, and et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences Br J Haematol 159 2 2012 154 163
82. M.L. Wang, S. Rule, P. Martin, and et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma N Engl J Med 369 6 2013 507 516
83. F. Cavalli, B. Rooney, L. Pei, H. Van De Velde, and T. Robak LYM-3002 Investigators. Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT) [abstract] J Clin Oncol 32 15, suppl 2014 8500
84. B.N. Nathwani, M.R. Drachenberg, A.M. Hernandez, A.M. Levine, and K. Sheibani Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma) Semin Hematol 36 2 1999 128 138
85. P.G. Isaacson Mucosa-associated lymphoid tissue lymphoma Semin Hematol 36 2 1999 139 147
86. C. Thieblemont, and B. Coiffier Management of marginal zone lymphomas Curr Treat Options Oncol 7 3 2006 213 222
87. I.A. Auer, R.D. Gascoyne, J.M. Connors, and et al. t(11;18)(q21;q21) is the most common translocation in MALT lymphomas Ann Oncol 8 10 1997 979 985
88. B. Alpen, A. Neubauer, J. Dierlamm, and et al. Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection [letter] Blood 95 12 2000 4014 4015
89. B. Streubel, A. Lamprecht, J. Dierlamm, and et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma Blood 101 6 2003 2335 2339
90. B. Streubel, U. Vinatzer, A. Lamprecht, M. Raderer, and A. Chott T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma Leukemia 19 4 2005 652 658
91. T. Wündisch, C. Thiede, A. Morgner, and et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication J Clin Oncol 23 31 2005 8018 8024
92. A. Conconi, G. Martinelli, C. Thiéblemont, and et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type Blood 102 8 2003 2741 2745
93. S. Wöhrer, B. Kiesewetter, J. Fischbach, and et al. Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis Ann Hematol 93 8 2014 1287 1295
94. M.A. Rizvi, A.M. Evens, M.S. Tallman, B.P. Nelson, and S.T. Rosen T-cell non-Hodgkin lymphoma Blood 107 4 2006 1255 1264
95. V. Mak, J. Hamm, M. Chhanabhai, and et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors J Clin Oncol 31 16 2013 1970 1976
96. N. Schmitz, L. Trümper, M. Ziepert, and et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group Blood 116 18 2010 3418 3425
97. S.M. Ansell, T.M. Habermann, P.J. Kurtin, and et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma J Clin Oncol 15 6 1997 2296 2301
98. B. Coiffier, B. Pro, H.M. Prince, and et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy J Clin Oncol 30 6 2012 631 636
99. O.A. O'Connor, B. Pro, L. Pinter-Brown, and et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study J Clin Oncol 29 9 2011 1182 1189
100. A. Dodero, F. Spina, F. Narni, and et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect Leukemia 26 3 2012 520 526